SCHEMBL1734274

SCHEMBL1734274

CCN(CC)c1nc(C(N)=O)cc(-c2cccc(C(=O)OC(C)C)c2)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.66
SMN1; SMN2 Q16637 4/20 0.41
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
GRM1 Q13255 1/20 0.37
JMJD6 Q6NYC1 1/20 0.35
SCN9A Q15858 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734575 0.88 KDM4E (0.70) KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL1734527 0.81 KDM4E (0.70) KDM4ESMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL1733513 0.81 KDM4E (0.77) KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL1733607 0.80 KDM4E (1.00) KDM4ESMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL1734461 0.80 KDM4E (0.72) KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL1733687 0.80 KDM4E (0.75) KDM4ENPC1RAB9ASCN9A
SCHEMBL1733619 0.80 KDM4E (0.75) KDM4EMEN1KMT2AGLAMAPT
SCHEMBL1735802 0.79 KDM4E (0.73) KDM4EALDH1A1MEN1KMT2AGLA
SCHEMBL1734592 0.79 KDM4E (0.66) KDM4ESMN1; SMN2ALDH1A1GLAHPGD
SCHEMBL1733738 0.77 KDM4E (0.70) KDM4EALDH1A1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
CN-101223146-A Modulators of ATP-binding cassette transporters VERTEX PHARMA (US) 2008-07-16 CN claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885SMN1; SMN2 4832/4885ALDH1A1 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.